STLN insider filings
Starling Oncology, Inc. — 9 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-19. Screen STLN transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 8 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing by 1 insider — 48,294 shares, $176,273 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 2 legs across 2 filings by 2 insiders — 3,149,914 shares, $13,322,043 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 10.
- Largest priced transaction: sale of 2,851,061 shares @ $3.99 ($11,375,733) by Chernett Jorey, filed 2026-11-10.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Chernett Jorey — 10% owner | 3 | 1 leg · 48,294 sh · $176,273 | 1 leg · 2,851,061 sh · $11,375,733 | 6 |
| Hively Brad — Director | 1 | — | 1 leg · 298,853 sh · $1,946,310 | — |
| Podnos Yale — Chief Medical Officer | 2 | — | — | 2 |
| Carter Robert Ross — Chief Financial Officer | 1 | — | — | 1 |
| Virnich Daniel — Chief Executive Officer | 1 | — | — | 1 |
Recent insider filings — Starling Oncology, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-19 | 4 | Virnich Daniel — Chief Executive Officer | Other (J): 5,102 @ $3.40 | EDGAR |
| 2026-11-19 | 4 | Carter Robert Ross — Chief Financial Officer | Other (J): 138 @ $3.40 | EDGAR |
| 2026-11-19 | 4 | Podnos Yale — Chief Medical Officer | Other (J): 1,271 @ $3.40 | EDGAR |
| 2026-11-17 | 4 | Podnos Yale — Chief Medical Officer | Other (J): 770 @ $3.76 | EDGAR |
| 2026-11-13 | 4/A | Chernett Jorey — 10% owner | Purchase (P): 1,391 (derivative) @ $0.80 | EDGAR |
| 2026-11-12 | 4 | Chernett Jorey — 10% owner | Purchase (P): 1,391 (derivative) @ $0.80 | EDGAR |
| 2026-11-10 | 4 | Chernett Jorey — 10% owner | Sale (S): 2,851,061 @ $3.99 · Purchase (P): 48,294 @ $3.65 · Purchase (P): 10,000 (derivative) @ $0.07 · Purchase (P): 5,000 (derivative) @ $0.40 · Purchase (P): 7,500 (derivative) @ $0.54 · Purchase (P): 7,000 (derivative) @ $0.67 | EDGAR |
| 2026-08-24 | 4 | Hively Brad — Director | Sale (S): 298,853 @ $6.51 | EDGAR |
| 2026-08-17 | 4 | Chernett Jorey — 10% owner | Purchase (P): 12,000 @ $6.54 · Sale (S): 100 (derivative) @ $6.24 | EDGAR |
Recent 8-K events — Starling Oncology, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-12 | 8-K/A | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-02 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-08-21 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-03 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-07 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-18 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-22 | 8-K | ? 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=STLN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs